Видео ютуба по тегу David Avigan

Investigating vaccines for hem-onc: key questions
Investigating vaccines for hem-onc: key questions
Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease
Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease
Laboratory Assessment of Immune Functioning | Doctors Avigan and Ludwig | IMS 2023
Laboratory Assessment of Immune Functioning | Doctors Avigan and Ludwig | IMS 2023
AML: Vaccination, hypomethylation and CAR-T
AML: Vaccination, hypomethylation and CAR-T
Cellular Immunotherapy for the Treatment of Multiple Myeloma
Cellular Immunotherapy for the Treatment of Multiple Myeloma
Utilizing combination therapies for multiple myeloma
Utilizing combination therapies for multiple myeloma
Dendritic cell vaccine for MM: Trial updates with maintenance & checkpoint inhibitor pidilizumab
Dendritic cell vaccine for MM: Trial updates with maintenance & checkpoint inhibitor pidilizumab
Immunotherapeutic approaches to myeloma
Immunotherapeutic approaches to myeloma
Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Dela...
Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Dela...
MMRF 25 Voices - Dr. David Avigan
MMRF 25 Voices - Dr. David Avigan
The role of vaccines in AML
The role of vaccines in AML
David Avigan on Precision Immuno
David Avigan on Precision Immuno
Multiple Myeloma Clinical Trial
Multiple Myeloma Clinical Trial
MMRF Immunotherapy Kick-Off: David Avigan
MMRF Immunotherapy Kick-Off: David Avigan
Message from Dr David Avigan
Message from Dr David Avigan
Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
Dendritic cell vaccine for MM: progress so far
Dendritic cell vaccine for MM: progress so far
Voices of BIDMC Research: Creating & Testing Cancer Vaccines
Voices of BIDMC Research: Creating & Testing Cancer Vaccines
CAR-T: hurdles and ladders
CAR-T: hurdles and ladders
FAQs on Clinical Trials: What Every Patient Should Know
FAQs on Clinical Trials: What Every Patient Should Know
David E. Avigan, MD, Immune Therapy and Immunology
David E. Avigan, MD, Immune Therapy and Immunology
Multiple Myeloma Symposium: Immunology| Dana-Farber Cancer Institute
Multiple Myeloma Symposium: Immunology| Dana-Farber Cancer Institute
How can a patient be proactive in their care and treatment?
How can a patient be proactive in their care and treatment?
Are myeloma experts open to scheduling second-opinion visits?
Are myeloma experts open to scheduling second-opinion visits?
Myeloma Crowd Radio: Dr. David Avigan, MD, Beth Israel Deaconess Medical Center
Myeloma Crowd Radio: Dr. David Avigan, MD, Beth Israel Deaconess Medical Center